Global Glaucoma Treatment Market: Trends and Opportunities (2014-2019) September 2014
View Report Details Scope of the Report The report titled “Global Glaucoma Treatment Market: Trends and Opportunities (2014-2019)” provides an insight into the glaucoma treatment market over the years with a special focus on major categories- pharmaceuticals and devices. The report includes detailed information on market size and share by type of drugs in glaucoma treatment sector. It also discusses key growth drivers, challenges and trends of the market. Further, companies like Pfizer Inc, Merck & Co, Allergan Inc and Alcon (Division of Novartis) are profiled in the report. Segments Coverage Θ
The US
Θ
Japan
Company Coverage Θ
Pfizer Inc
Θ
Merck & Co
Θ
Allergan Inc
Θ
Alcon (Division of Novartis)
Executive Summary
Glaucoma, the second most common cause of blindness worldwide is generally characterized by relatively high intraocular pressure (IOP) as a result of impaired drainage of fluid, known as aqueous humor, from the eye. Currently approved treatments for glaucoma include a number of pharmaceutical drugs, laser therapies and surgical procedures. Glaucoma treatment forms a significant portion of the overall eye care market. The market for glaucoma treatment has grown rapidly in the last decade, based on both increasing number of people with glaucoma and the introduction of new treatments. However, the worldwide glaucoma treatment market is expected to decline that can be attributable to price reduction of drugs due to generic availability of many brands in coming years. The glaucoma pharmaceuticals are segmented into two classes namely prostaglandins analogues (PGAs) and Non PGAs that include beta blockers, carbonic anhydrase inhibitors and alpha agonists. PGAS are the most widely prescribed drug class for glaucoma with latanoprost (brand name Xalatan) the most commonly prescribed drug. Key growth drivers of the market include rising ageing population, healthcare expenditures, medical coverage and new innovative combination drugs. The market players in medication as well as devices segments are totally different and somewhat very fragmented. Leaders in glaucoma medication space include Pfizer Inc, Alcon Inc. (Novartis), Allergan Inc and Merck and Co, Inc. Companies developing glaucoma drug-delivery devices include Ocular Therapeutix Inc, QLT Inc, pSivida Corp, Icon Bioscience Inc, Amorphex Therapeutics LLC, Euclid Systems Corp and Replenish Inc. In glaucoma laser market, top market leaders include Ellex, Lumenis, Quantel and Lightmed.
Global Glaucoma Treatment Market: An Overview The worldwide glaucoma treatment market decreased from US$.... billion in 2010 to US$..... billion in 2013. The decline can be attributed to price reduction of drugs due to generic availability of many brands in coming years. Nearly ‌. million people are expected to develop glaucoma by 2020.
Global Glaucoma Treatment Market Sales in US$ Billion, 2010-2013
Market Share of Commonly Prescribed Glaucoma Drugs in %, 2013
Prostaglandins Beta-Blockers Beta-blocker fixed combos Alpha agonists Carboic anhydrase inhibitors 2010
2011
2012
2013
• Prostaglandins (PGA) are the most widely prescribed drug class for glaucoma. Beta blockers are the second most widely prescribed class for glaucoma and timolol (brand names Timoptic, Istalol, etc.) is the most widely prescribed beta blocker.
Global Glaucoma Devices Market Worldwide sales of medical devices to diagnose and treat glaucoma were reported at US$... million in 2013, an increase of ….% from 2008. The emergence of high-growth glaucoma devices based on minimally invasive surgical implants and introduction of new technologies are driving the sales. Global Glaucoma Devices Market Size in US$ Million, 2008-2013
Global Glaucoma Devices Market Segmentation in %, 2013
GDD SUSD Glaucoma Lasers Surgical Instruments Surgical Systems
2008
2009
2010
2011
2012
2013
• The SUSD (Single Use Surgical Devices) category includes stents and implants, but these require invasive surgery. This segment accounted for …% of glaucoma devices market followed by lasers (…%), surgical instruments (….%) and surgical systems (….%).
3. Global Eye Care Market Analysis 3.1 Market Size
Table of Contents
3.2 Market Segments 3.3 Surgical Market 3.4 Ophthalmic Pharmaceuticals Market 3.5 Vision Care Market 4. Global Glaucoma Treatment Market: An Analysis 4.1 Market Size 4.2 Share by Type of Drugs 4.3 Glaucoma Devices Market 5. Regional Analysis: Glaucoma Treatment Market 5.1 The US 5.2 Japan 6. Market Dynamics: Global Glaucoma Treatment Market 6.1 Growth Drivers 6.1.1 Rising Ageing Population 6.1.2 Rising Healthcare Expenditures 6.1.3 New Glaucoma Drug Delivery Devices 6.2 Key Issues 6.2.1 Strict Regulation and Marketing Approval
8. Company Profiles 8.1 Pfizer Inc. 8.1.1 Business Description 8.1.2 Financial Overview 8.1.3 Business Strategies 8.2 Merck & Co., Inc. 8.2.1 Business Overview 8.2.2 Financial Overview 8.2.3 Business Strategies 8.3 Allergan Inc. 8.3.1 Business Description 8.3.2 Financial Overview 8.3.3 Business Strategies 8.4 Alcon (Division of Novartis) 8.4.1 Business Description 8.4.2 Financial Overview 8.4.3 Business Strategies 9. About Us
Table of Contents
List of Charts Figure 1: Diagram of the Structure of the Eye (left) and Damage from Glaucoma (Right) Figure 2: Global Eye Care Market Size in US$ Billion, 2013-2018F Figure 3: Global Eye Care Market Segmentation in %, 2013 Figure 4: Breakup of Global Eye Surgical Market in US$ Billion, 2013 Figure 5: Breakup of Global Ophthalmic Pharmaceuticals Market in US$ Billion, 2013 Figure 6: Breakup of Global Vision Care Industry in US$ Billion, 2013 Figure 7: Global Glaucoma Treatment Market Sales in US$ Billion, 2010-2013 Figure 8: Total Worldwide Glaucoma Market Annual Prescriptions in Million, 2012-2019F Table 1: Commonly Used Glaucoma Medications with Generic Equivalents Figure 9: Forecast Global Glaucoma Treatment Market in US$ Billion, 2014F-2019F Figure 10: Market Share of Commonly Prescribed Glaucoma Drugs in %, 2013 Figure 11: Global Glaucoma Devices Market Size in US$ Million, 2008-2013 Figure 12: Global Glaucoma Devices Market Segmentation in %, 2013 Figure 13: The US Glaucoma Market Sales in US$ Billion, 2012-2020F Figure 14: The US Glaucoma Market Annual Prescriptions in Million, 2012-2020F Figure 15: The US Glaucoma Market Composition in %, 2013 Figure 16: The US Prostaglandin Market Sales and Annual Prescriptions, 2012-2020F Table 2: The US – Xalatan (latanoprost) Estimated Glaucoma Market, 2012-2020F Table 3: The US - Lumigan (bimatoprost) Estimated Glaucoma Market (AGN), 2012-2020F Table 4: The US – Travatan (travoprost) Estimated Glaucoma Market, 2012-2020F Table 5: The US – Zioptan Estimated Glaucoma Market, 2012-2020F
List of Charts Figure 17: The US Beta Blocker Market Sales and Annual Prescriptions, 2012-2020F Figure 18: The US Combination Glaucoma Market Sales and Annual Prescriptions, 2012-2020F Table 6: The US - Combigan Estimated Glaucoma Market (AGN), 2012-2020F Table 7: The US - Cosopt Estimated Glaucoma Market (AGN), 2012-2020F Table 8: The US - Simbrinza Estimated Glaucoma Market (NVS/Alcon), 2013-2020F Figure 19: The US Carbonic Anhydrase Market Sales and Annual Prescriptions, 2012-2020F Table 9: The US – Carbonic Anhydrase Inhibitors (Branded) Estimated Glaucoma Market, 2012-2020F Table 10: The US – Carbonic Anhydrase Inhibitors (Generics) Estimated Glaucoma Market, 2012-2020F Figure 20: Japan Prescription Ophthalmic Pharmaceuticals Market in US$ Billion, 2009-2013 Figure 21: Japan Prescription Ophthalmic Pharmaceuticals Market Segmentation in %, 2013 Figure 22: Japan Glaucoma Treatment Market in US$ Million, 2012-2013 Figure 23: Global Total Population ages 65 and above in Million, 2007-2013 Figure 24: Global Healthcare Expenditures Per Capita in US$, 2007-2013 Figure 25: Share of Monotherapies and Combinations Glaucoma Drugs in %, 2013 versus 2018F Figure 26: Shares of Global Ophthalmic Laser Market Players in %, 2013 Figure 27: Pfizer’s Revenue Share by Business Segments in %, 2013 Figure 28: Pfizer – Revenues from Xalatan/Xalacom in US$ Million, 2011-2013 Figure 29: Merck & Co., Inc. Revenue by Business Segment in %, 2013 Figure 30: Merck & Co., Inc – Revenue from Cosopt/Trusopt in US$ Million, 2011-2013 Figure 31: Allergan Inc Business Segmentation by Revenue in %, 2013 Figure 32: Allergan – Revenue from Total Glaucoma Products in US$ Million, 2011-2013
List of Charts Figure 33: Revenue from Alcon Division in US$ Million, 2011-2013 Table 11: Alcon - Ophthalmic Projects/Products Planned in Coming Years
Title: Global Glaucoma Treatment Market: Trends and Opportunities (2014-2019) Published: September 2014 Pages: 66 Price: US$ 800 (Single-User License) : US$ 1600 (Corporate License) For placing an order of the Report, please press the following link: http://www.daedal-research.com/global-glaucoma-treatment-market-trends-and-opportunities-2014-2019
For more details please contact Mr. Rajeev Kumar: Tel: +91-120-4553017 (9.30 am - 6.30 pm) IST Mobile: +91-8743975789 (24 X7) Enquiries: info@daedal-research.com
Daedal Research
Daedal Research is a research and consulting firm specialized in providing research reports and customized business research and analysis. The research firm offers a blend of the best strategic consulting and market research solutions, which promise data rich, cost effective, and highly insightful analysis to help its clients with perfect answers to their important business queries .